Application of pharmacogenomics in clinical pharmacology

被引:27
作者
Huang, SM [1 ]
Goodsaid, F [1 ]
Rahman, A [1 ]
Frueh, F [1 ]
Lesko, LJ [1 ]
机构
[1] US FDA, Off Clin Pharmacol & Biopharmaceut, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
基金
美国国家科学基金会;
关键词
pharmacogenomics application; clinical pharmacology;
D O I
10.1080/15376520600558333
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Many factors can affect a patient's response to a drug. These include intrinsic factors such as age, gender, race/ethnicity, genetics, disease states, organ dysfunctions, and other physiological changes, including pregnancy, lactation, and extrinsic factors such as smoking, diet ( food, juice, dietary supplements), and concomitant medications (ICH E5, 1998 and 2004). The interplay of genotypes of the enzymes, transporters and receptors, among other factors ( such as concomitant medications and disease states), can affect the risk/benefit ratio for individual patients. This commentary discusses when the genomic information should be obtained during drug development and when it is to be assimilated into labeling and standards of care that can be used to "individualize" drug therapy and become one of the pillars of "personalized medicine."
引用
收藏
页码:89 / 99
页数:11
相关论文
共 91 条
[61]   Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1) [J].
Pauli-Magnus, C ;
Kroetz, DL .
PHARMACEUTICAL RESEARCH, 2004, 21 (06) :904-913
[62]   CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy [J].
Peyvandi, F ;
Spreafico, M ;
Siboni, SM ;
Moia, M ;
Mannucci, PM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (03) :198-203
[63]   Potential role of pharmacogenomics in reducing adverse drug reactions - A systematic review [J].
Phillips, KA ;
Veenstra, DL ;
Oren, E ;
Lee, JK ;
Sadee, W .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (18) :2270-2279
[64]   Association of long QT syndrome loci and cardiac events among patients treated with β-blockers [J].
Priori, SG ;
Napolitano, C ;
Schwartz, PJ ;
Grillo, M ;
Bloise, R ;
Ronchetti, E ;
Moncalvo, C ;
Tulipani, C ;
Veia, A ;
Bottelli, G ;
Nastoli, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (11) :1341-1344
[65]  
RATAIN M, 2004, FDA PHRMA JHU ED WOR
[66]   Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients [J].
Rouits, E ;
Boisdron-Celle, M ;
Dumont, A ;
Guérin, O ;
Morel, A ;
Gamelin, E .
CLINICAL CANCER RESEARCH, 2004, 10 (15) :5151-5159
[67]   Pharmacogenomic data submissions to the FDA:: clinical pharmacology case studies [J].
Ruaño, G ;
Collins, JM ;
Dorner, AJ ;
Wang, SJ ;
Guerciolini, R ;
Huang, SM .
PHARMACOGENOMICS, 2004, 5 (05) :513-517
[68]  
RUANO G, 2003, 52 ANN AM COLL CARD
[69]   UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer [J].
Sai, K ;
Saeki, M ;
Saito, Y ;
Ozawa, S ;
Katori, N ;
Jinno, H ;
Hasegawa, R ;
Kaniwa, N ;
Sawada, J ;
Komamura, K ;
Ueno, K ;
Kamakura, S ;
Kitakaze, M ;
Kitamura, Y ;
Kamatani, N ;
Minami, H ;
Ohtsu, A ;
Shirao, K ;
Yoshida, T ;
Saijo, N .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) :501-515
[70]   Pharmacogenomic data: FDA voluntary and required submission guidance [J].
Salerno, RA ;
Lesko, LJ .
PHARMACOGENOMICS, 2004, 5 (05) :503-505